Faculty Profiles - TOYOOKA Shinichi

Papers - TOYOOKA Shinichi

Division display 861 - 880 of about 940 ／ All the affair displays >>

Extensive traumatic pneumomediastinum. without injuries of organs in the thorax: report of a case

D. Okutani, M. Aoe, M. Yamane, S. Hatoh, S. Toyooka, Y. Sano, H. Date

Kyobu geka. The Japanese journal of thoracic surgery 60 ( 10 ) 942 - 945 2007

Language：Japanese Publishing type：Research paper (scientific journal)

A 57-year-old man was accidentally hit by concrete blocks weighing 3 tons on his right side, and was admitted to a hospital. The radiologic findings taken immediately after trauma demonstrated pneumo-mediastinum, subcutaneous emphysema with multiple rib fractures and right clavicle fracture. At computed tomography (CT) scan 16 hours after trauma, pneumomediastinum and subcutaneous emphysema turned out to be worsened with an increased bilateral pleural effusion. An emergency thoracotomy revealed no abnormalities of trachea or esophagus, and neither bronchoscopy or esophagogastroscopy, showed injuries anywhere inside. The chest cavities and mediastinum were washed well with 3 liters of saline solution. The patient had a good course after surgery without any complications, and was discharged at the 18th hospital day. Mediastinal drainage by an emergency operation should always be a choice to a patient having a progressively worsening pneumomediastinum which might cause tachycardia, low blood pressure, and severe dyspnea due to compression of blood vessels and trachea.

Scopus

PubMed

researchmap

The impact and role of EGFR gene mutation on non-small cell lung cancer Reviewed

Shinichi Toyooka, Junichi Soh, Hisayuki Shigematsu, Motoi Aoe, Hiroshi Date

CANCER CHEMOTHERAPY AND PHARMACOLOGY 58 S25 - S31 2006.11

Language：English Publishing type：Research paper (scientific journal) Publisher：SPRINGER

Mutations in the epidermal growth factor receptor (EGFR) gene have been reported in non-small cell lung cancer (NSCLC), especially in patients with adenocarcinomas, women, never smokers, and East Asians. These factors were recognized as predictors of gefitinib response in the Iressa Dose Evaluation in Advanced Lung Cancer study. Despite some contradictory arguments, somatic mutations in EGFR have been demonstrated to be a useful biomarker for predicting the clinical outcome of treatment with gefitinib or erlotinib, indicating the necessity of validated assays for clinical applications. Mutations in EGFR and KRAS are established carcinogenic mechanisms responsible for NSCLC. Recent studies have demonstrated that epigenetic alteration is another critical mechanism in lung carcinogenesis. Notably, EGFR and KRAS mutations are mutually exclusive, suggesting the presence of two independent pathways for the development of adenocarcinoma; however, the relationship between mutation and epigenetic alteration is not known. To address these issues, we examined the EGFR mutation status in Japanese patients with NSCLC by direct sequencing exons 18-21 of EGFR; the results were then correlated with clinicopathological factors and previously investigated epigenetic alterations. In this article, we mainly focus on: (1) the relationship between EGFR mutations and clinicopathological factors, (2) the relationship between EGFR mutations and response to gefitinib, (3) the development of a sensitive assay for detecting the major EGFR mutations, and (4) differences in the evolution of epigenetic alterations between EGFR- or KRAS-mediated tumorigenesis. The present results provide important data for translational research and will further our understanding of the molecular pathogenesis of NSCLC, leading to the establishment of molecular targeting strategies for the treatment of NSCLC.

DOI： 10.1007/s00280-006-0312-8

Web of Science

researchmap

肺癌診断のフロントライン肺癌手術症例における術前、術中診断方法(特に胸腔鏡下生検)について

青江基, 越宗龍一郎, 市原周治, 末久弘, 宗淳一, 柿下大一, 堀志郎, 奥谷大介, 平見有二, 山根正修, 豊岡伸一, 佐野由文, 伊達洋至

日本臨床外科学会雑誌 67 ( 増刊 ) 267 - 267 2006.10

胸水中EGFR遺伝子変異がゲフィチニブによる生存延長効果の予測因子になりうるか

宗淳一, 豊岡伸一, 浅野博昭, 青江基, 佐野由文, 清水信義, 伊達洋至, 青江啓介, 片山英樹, 杉和郎, 木浦勝行

肺癌 46 ( 6 ) 783 - 784 2006.10

性別・喫煙歴が肺癌におけるEGFR遺伝子変異部位に及ぼす影響についての検討

豊岡伸一, 松尾恵太郎, 重松久之, 徳毛誠樹, 犬飼道雄, 市原周治, 末久弘, 宗淳一, 木浦勝行, 山根正修, 青江基, 佐野由文, 伊達洋至

日本癌学会総会記事 65回 454 - 454 2006.9

CT腫瘍径20mm以下、臨床病期1A原発性非小細胞肺癌における再発危険因子の検討

小林成行, 豊岡伸一, 宗淳一, 山根正修, 青江基, 佐野由文, 伊達洋至

The Japanese Journal of THORACIC AND CARDIOVASCULAR SURGERY 54 ( Suppl. ) 384 - 384 2006.9

非小細胞肺癌におけるゲフィチニブの臨床効果とHER2、EGFR遺伝子異常の関係

豊岡伸一, 宗淳一, 市原周治, 末久弘, 犬飼道雄, 重松久之, 山根正修, 青江啓介, 青江基, 佐野由文, 清水信義, 伊達洋至

The Japanese Journal of THORACIC AND CARDIOVASCULAR SURGERY 54 ( Suppl. ) 480 - 480 2006.9

胸水中EGFR遺伝子変異検索に基づいた肺癌個別化治療の可能性

宗淳一, 豊岡伸一, 青江啓介, 浅野博昭, 市原周治, 末久弘, 重松久之, 山根正修, 青江基, 佐野由文, 杉和郎, 清水信義, 伊達洋至

The Japanese Journal of THORACIC AND CARDIOVASCULAR SURGERY 54 ( Suppl. ) 340 - 340 2006.9

非小細胞肺癌におけるゲフィチニブの臨床効果とHER2、EGFR遺伝子異常の関係

宗淳一, 豊岡伸一, 市原周二, 青江啓介, 山根正修, 青江基, 佐野由文, 藤原義朗, 堀田勝之, 木浦勝行, 伊達洋至

日本癌学会総会記事 65回 234 - 234 2006.9

gefitinib抵抗性肺癌におけるT790M変異の存在と臨床的意義

犬飼道雄, 豊岡伸一, 浅野博昭, 市原周治, 宗淳一, 山根正修, 青江基, 佐野由文, 清水信義, 伊達洋至

日本癌治療学会誌 41 ( 2 ) 671 - 671 2006.9

変異型EGFR発現非小細胞肺癌細胞株のRas12V導入によるgefitinib耐性化

内田亜希子, 平野世紀, 北尾洋之, 頼冠名, 荻野敦子, 豊岡伸一, 瀧川奈義夫, 田端雅弘, 高田穣, 木浦勝行, 谷本光音

日本癌学会総会記事 65回 234 - 234 2006.9

非喫煙歴による術後再発非小細胞肺癌患者の長期生存予測(Never-smoking history predicts long-term survival in patients with non-small cell lung cancer with postoperative recurrence)

藤原義朗, 木浦勝行, 田端雅弘, 瀧川奈義夫, 谷本安, 堀田勝幸, 松尾恵太郎, 豊岡伸一, 佐野由文, 青江基, 伊達洋至, 谷本光音

日本癌治療学会誌 41 ( 2 ) 671 - 671 2006.9

OKT3が有用であった生体肺移植後のステロイド抵抗性急性拒絶反応の検討

杉本誠一郎, 伊達洋至, 杉本龍士郎, 吉田修, 豊岡伸一, 青江基, 岡部和倫, 佐野由文

日本呼吸器外科学会雑誌 20 ( 3 ) 812 - 812 2006.5

術後再発非小細胞肺癌に対するGefitinib治療効果とEGFR遺伝子変異・コピー数異常の検討

市原周治, 豊岡伸一, 徳毛誠樹, 宗淳一, 藤原義朗, 重松久之, 末久弘, 青江啓介, 青江基, 佐野由文, 岡部和倫, 杉和郎, 木浦勝行, 伊達洋至, 清水信義

日本呼吸器外科学会雑誌 20 ( 3 ) 794 - 794 2006.5

腫瘍径20mm以下のc-1A肺腺癌症例における早期再発予測因子

小林成行, 豊岡伸一, 宗淳一, 青江基, 岡部和倫, 佐野由文, 伊達洋至, 清水信義

日本呼吸器外科学会雑誌 20 ( 3 ) 939 - 939 2006.5

Enriched PCR法による胸水中EGFR遺伝子変異検索に基づいた肺癌個別化治療の可能性

宗淳一, 豊岡伸一, 浅野博昭, 市原周治, 重松久之, 青江啓介, 青江基, 佐野由文, 岡部和倫, 杉和郎, 伊達洋至, 清水信義

日本呼吸器外科学会雑誌 20 ( 3 ) 794 - 794 2006.5

非小細胞肺癌切除症例におけるEGFR遺伝子変異と臨床病理学的因子の検討

豊岡伸一, 市原周治, 徳毛誠樹, 小林成行, 脇直久, 宗淳一, 末久弘, 浅野博昭, 重松久之, 青江基, 岡部和倫, 佐野由文, 伊達洋至, 清水信義

日本呼吸器外科学会雑誌 20 ( 3 ) 843 - 843 2006.5

Infrequent existence of simian virus 40 large T antigen DNA in malignant mesothelioma in Japan Reviewed

Keisuke Aoe, Akio Hiraki, Tomoyuki Murakami, Shinichi Toyooka, Narayan Shivapurkar, Adi F. Gazdar, Naoko Sueoka, Koji Taguchi, Toshiaki Kamei, Hiroyasu Takeyama, Kazuro Sugi, Takumi Kishimoto

Cancer Science 97 ( 4 ) 292 - 295 2006.4

Language：English Publishing type：Research paper (scientific journal)

Malignant mesothelioma is the most common primary pleural neoplasm. Association of simian virus 40 (SV40) with malignant mesothelioma has been reported, suggesting that SV40 plays an important role in the origin of a subset of these tumors. However, significant geographic variation is present as to how often this association occurs. As no study concerning SV40 in malignant mesothelioma has been reported from Japan, we examined the frequency of SV40 infection in Japanese malignant mesothelioma cases. In pleural malignant mesothelioma tissue from 35 patients in Japan, we sought the presence of SV40 large T antigen DNA using real-time polymerase chain reaction (PCR), as well as expression of the viral protein using immunohistological methods. Real-time PCR demonstrated that two of 35 mesotheliomas contained DNA sequences encoding portions of SV40 large T antigen. None of the 35 malignant mesothelioma specimens showed immunoreactivity for SV40 large T antigen. SV40 infection does not appear to have a major role in the development of malignant mesothelioma in Japan. © 2006 Japanese Cancer Association.

DOI： 10.1111/j.1349-7006.2006.00171.x

Scopus

PubMed

researchmap

Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer. Reviewed International journal

Fujiwara Y, Kiura K, Toyooka S, Takigawa N, Tokumo M, Hotta K, Aoe M, Tabata M, Matsuo K, Date H, Tanimoto M

Lung cancer (Amsterdam, Netherlands) 52 ( 1 ) 99 - 103 2006.4

Language：English Publishing type：Research paper (scientific journal) Publisher：1

PURPOSE: Recent reports have demonstrated that mutation of epidermal growth factor receptor (EGFR) gene is predictive factor for tumor responsiveness to gefitinib suggesting the importance of EGFR status for the treatment of the patients with non-small cell lung cancer (NSCLC). However, the relationship between EGFR mutation and adverse events of gefitinib is still unknown. The aim of this study was to evaluate its correlation. PATIENTS AND METHODS: Twenty-six tumor samples from Japanese NSCLC patients who received gefitinib in Okayama University Hospital between November 2000 and October 2004 were examined exons 18-21 of EGFR using direct sequence method. We retrospectively reviewed the clinical records and compared EGFR mutation status with adverse events during gefitinib treatment. RESULTS: Of all 26 patients, EGFR mutation (exon 19 in-frame deletion, 6; exon 21 L858R, 5), were detected in 11 patients (42.3%). The principal adverse event was skin rash (89%), diarrhea (39%), and liver injury (39%). Grade 3 or more adverse events were not common. EGFR mutation status was correlated with neither its frequency nor severity of adverse events during gefitinib treatment including skin rash, diarrhea, liver injury, and interstitial lung disease. As expected, objective response rate of those with EGFR mutations was significantly higher than those without EGFR mutations (78% versus 21%, P<0.001). CONCLUSION: Our study did not demonstrate the presence of close relationships between EGFR mutation status and adverse events during gefitinib treatment.

DOI： 10.1016/j.lungcan.2005.12.004

Scopus

PubMed

researchmap

Other Link： http://orcid.org/0000-0003-1761-6314

Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung. Reviewed

Toyooka S, Yatabe Y, Tokumo M, Ichimura K, Asano H, Tomii K, Aoe M, Yanai H, Date H, Mitsudomi T, Shimizu N

International journal of cancer 118 ( 6 ) 1588 - 1590 2006.3

　 PREV - NEXT 　

< TOYOOKA Shinichi >

Papers - TOYOOKA Shinichi